lucadezzani
Luca Dezzani
Luca Dezzani is an MD working as Global Medical Director at Novartis Oncology Headquarters | IgeaHub.com
422 posts
Don't wanna be here? Send us removal request.
Last Seen Blogs
vitortol-blog
Realidade Alternativa
alunasky-blog
Alunasky
raouls-inferno
that handsome devil !
akaza
CETUS
blessingses
h/rny
Text
Top 10 LOEs Before The End Of 2018
Top 10 LOEs Before The End Of 2018
The complete list and analysis of the major blockbusters that will loose exclusivity by the end of 2018. All the pharmaceutical companies facing generic and biosimilar competition.
With each passing year, more drugs lose their patent protection. Loss of exclusivity (LOE) brings a mix of feelings: while it is bad news for the parent company, it is good news for other companies who have been…
View On WordPress
0 notes
Text
Top News from the Annual Meeting of the European Association for the Study of Diabetes #EASD2018
Top News from the Annual Meeting of the European Association for the Study of Diabetes #EASD2018
All The Most Important News and Updates form the 54th Annual Meeting of the European Association for the Study of Diabetes – EASD 2018 People with diabetes may achieve improved glycaemic control with Tresiba® versus glargine U100, without an increase in hypoglycaemia
October 2, 2018
According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may…
View On WordPress
#2018#albiglutide#AstraZeneca#Boehringer Ingelheim#Bydureon#Duke Clinical Research Institute#EASD#Eli Lilly and Company#empagliflozin#Farxiga#GIP/GLP-1 RA#GSK#Novo Nordisk#Ryzodeg#Tresiba
0 notes
Text
Top Pharma News of the Week – October 8th
Top Pharma News of the Week – October 8th
All The Most Important Pharmaceutical News Stories Of The Week – October 2018 – Week # 2 Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
October 3, 2018
Novartis has announced that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis…
View On WordPress
#Akcea Therapeutics#Arrowhead Pharmaceuticals#baloxavir marboxil#Boston Pharmaceuticals#Hemlibra#Ionis Pharmaceuticals#Janssen#Loxo Oncology#LOXO-292#Novartis#Roche#siponimod#SYMTUZA#TEGSEDITM
0 notes
Text
Top Pharma News of the Week – October 1st
Top Pharma News of the Week – October 1st
All The Most Important Pharmaceutical News Stories Of The Week – October 2018 – Week # 1 BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
September 24, 2018
Amgen has announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed…
View On WordPress
#Advent#AMGen#AstraZeneca#BLINCYTO#Bydureon#Eli Lilly and Company#Emgality#GSK#Libtayo#M72/AS01E#Pfizer#sanofi#VIZIMPRO
0 notes
Text
Top News from the IASLC 19th World Conference on Lung Cancer 2018 #WCLC2018
Top News from the IASLC 19th World Conference on Lung Cancer 2018 #WCLC2018
All The Most Important News and Updates form the International Association for the Study of Lung Cancer 19th World Conference – IASLC WCLC 2018 Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
September 24, 2018
Roche has announced results for its investigational medicine entrectinib, from an integrated…
View On WordPress
#2018#ALUNBRIG#AstraZeneca#BrigAtinib#Daiichi Sankyo#Dolaflexin#EarlyCDT#entrectinib#IASLC#Imfinzi#Loxo Oncology#LOXO-292#Lung Cancer#Mersana Therapeutics#Oncimmune Holdings#Takeda#TECENTRIQ®#trastuzumab deruxtecan
0 notes
Text
Top Pharma News of the Week – September 24th
Top Pharma News of the Week – September 24th
All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 4 FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 20, 2018
ACADIA Pharmaceuticals Inc. has announced that the FDA has completed a postmarketing review and…
View On WordPress
#ACADIA Pharmaceuticals#ADCETRIS#ALUNBRIG#brolucizumab#DELSTRIGO#GlaxoSmithKline#Luxturna#Merck#Novartis#NUPLAZID#pegfilgrastim#PIFELTRO#St. Jude Children’s Research Hospital#Takeda#Tessa Therapeutics#Trelegy Ellipta
0 notes
Text
Top 10 Consumer Health Companies 2018
Top 10 Consumer Health Companies 2018
The complete review and analysis of the 10 best Consumer Health Companies in 2018.
Consumer health companies deals with products in wellness, oral health, nutrition, and skin health. These consumer healthcare products primarily include the “over-the-counter” (OTC) drugs that are sold without a prescription from registered medical practitioner. Globally large number of acquisitions, mergers,…
View On WordPress
0 notes
Text
Top News from ERS International Congress 2018
Top News from ERS International Congress 2018
All The Most Important News and Updates form the European Respiratory Society International Congress – ERS 2018 People with asthma at higher risk of becoming obese
September 15, 2018
Obesity is known to be a risk factor for developing asthma but a new study shows that the reverse is also true: people with asthma are more likely to go on to become obese. The new research, presented at the European…
View On WordPress
#2018#air pollution#Anticalin#Asthma#AstraZeneca#Congress#COPD#ERS#Fasenra#green spaces#KRONOS#Obesity#paracetamol#Pieris Pharmaceuticals#PRS-060
0 notes
Text
Top Pharma News of the Week - September 17th
Top Pharma News of the Week – September 17th
All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 3 Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis
September 11, 2018
Gilead Sciences, Inc. and Galapagos NV have announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an…
View On WordPress
#Allergan#BMS-986165#Boehringer Ingelheim#Bonti#Bristol-Myers Squibb#filgotinib#Galapagos#Gilead Sciences#Keytruda#Merck#Precision BioSciences#ViraTherapeutics#ZERBAXA
0 notes
Text
CAR-T Therapies in 2018
CAR-T Therapies in 2018
The Complete Review and Analysis of the Chimeric Antigen T Cell Receptors (CART-T) Programs and All the Main Players in the Pharmaceutical & Biotechnology Industry in 2018
Chimeric antigen receptors (CARs) are engineered receptors that are changed in the laboratory to combine as a new specificity with an immune cell to attack cancer cells. CARs bind the certain protein with specificity of a…
View On WordPress
0 notes
Text
Top Pharma News of the Week - September 10th
Top Pharma News of the Week – September 10th
All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 2 Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
September 3, 2018
The European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic…
View On WordPress
#AstraZeneca#Aurobindo Pharma#benralizumab#Cablivi#filgotinib#Gilead Sciences#GlaxoSmithKline#Jak3 Inhibitor#Loxo Oncology#LOXO-292#mepolizumab#Novartis#Nucala#Pfizer#reslizumab#sanofi#tezepelumab#Trianni
0 notes
Text
Best Pharmaceutical Companies - Quarterly Analysis - Q2 2018
Best Pharmaceutical Companies – Quarterly Analysis – Q2 2018
Here is the most comprehensive review and analysis of the quarterly results of the 10 best pharmaceutical companies. This series provide you with a regular performance update of the major pharmaceutical and biotechnology players
1. PFIZER
With a total revenue of $13.5 billion in the second quarter of 2018, Pfizer maintains…
View On WordPress
0 notes
Text
Top Pharma News of the Week - September 3rd
Top Pharma News of the Week – September 3rd
All The Most Important Pharmaceutical News Stories Of The Week – September 2018 – Week # 1 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
August 27, 2018
Novartis has announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young…
View On WordPress
#AMGen#anifrolumab#AstraZeneca#bayer#BLINCYTO#Bydureon BCise#DELSTRIGO#domagrozumab#Jivi#Kymriah#Merck#Novartis#Pfizer#PIFELTRO#Tafinlar
0 notes
Text
Top News from ESC Congress 2018
Top News from ESC Congress 2018
All The Most Important News and Updates form the European Society of Cardiology Congress – ESC 2018 AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018
August 25, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, presented new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio of…
View On WordPress
#2018#AstraZeneca#BELVIQ#CNIC#Congress#CVRM#Eisai#Emory University School of Medicine#Entresto#ESC#Janssen#Novartis#Pfizer#placebo#tafamidis#Xarelto
0 notes
Text
Evaluation of Clinical Trial Costs and Barriers to Drug Development
Evaluation of Clinical Trial Costs and Barriers to Drug Development
The complete analysis of the costs and barriers to drug development in 2018. All the expenses to conduct clinical trials and the split by disease areas
Clinical trials are a crucial part of the drug development process. Pharmaceutical companies conduct clinical trials to demonstrate safety and efficacy in order to gain approval from regulatory bodies. In recent times, the cost of clinical…
View On WordPress
0 notes
Text
Top Pharma News of the Week - August 27th
Top Pharma News of the Week – August 27th
All The Most Important Pharmaceutical News Stories Of The Week – August 2018 – Week # 4 Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer
August 21, 2018
AstraZeneca has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent…
View On WordPress
#AbbVie#Allergan#AstraZeneca#Bevespi Aerosphere#bluebird bio#BYL719#elagolix#Entresto#Gritstone Oncology#Kymriah#Novartis#Shire#Tagrisso#TAKHZYRO#ulipristal acetate
0 notes
Text
Top Pharma News of the Week - August 20th
Top Pharma News of the Week – August 20th
All The Most Important Pharmaceutical News Stories Of The Week – August 2018 – Week # 3 Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases
August 14, 2018
Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment of pulmonary diseases such as…
View On WordPress
#Alecensa#bayer#Eisai#Eylea#Haplogen#KALYDECO#Lenvima#Merck#Novo Nordisk#Opdivo#Regeneron#ristol-Myers Squibb#Roche#Vertex#Ziylo
0 notes